Repligen Corp
Research Repligen Corp (RGEN) on Bullrun: market cap USD 9.73B, P/E 235.1. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerRGEN
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryMedical Instruments & Supplies
- CurrencyUSD
- Market capUSD 9.73B
- P/E235.1
- Financial periodQ2 2026
- RevenueUSD 204.13M
- Net incomeUSD 5.01M
- Free cash flowUSD 26.70M
- Gross margin53.9%
Valuation Snapshot
latest market cap is USD 9.73B; P/E is 235.1.
Peer valuation comparison
Latest P/E is 235.12x versus a Healthcare sector median of 24.6x (855.8% above).
Latest P/E is 235.12x versus a United States median of 23.85x (885.7% above).
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 738.26M | USD 48.89M | USD 93.90M | 52.3% | 0.86 | USD 566.02M | USD 542.21M | USD 2.11B |
| FY2024 | USD 634.44M | -USD 25.51M | USD 149.72M | 43.3% | -0.46 | USD 757.36M | USD 525.57M | USD 1.97B |
| FY2023 | USD 632.36M | USD 35.60M | USD 77.70M | 44.0% | 0.63 | USD 751.32M | USD 711.80M | USD 1.96B |
| FY2022 | USD 801.54M | USD 185.96M | USD 87.25M | 56.9% | 3.24 | USD 523.46M | USD 422.96M | USD 1.91B |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-10-12 | USD 9.73B | 235.1 | n/a | n/a |
| 2025 | 2025-12-31 | USD 9.23B | 190.5 | n/a | n/a |
| 2024 | 2024-12-31 | USD 8.07B | n/a | n/a | n/a |
| 2023 | 2023-12-29 | USD 10.04B | 101.6 | n/a | n/a |
| 2022 | 2022-12-30 | USD 9.40B | 58.6 | n/a | n/a |
| 2021 | 2021-12-31 | USD 14.65B | 118.2 | n/a | n/a |
About Repligen Corp
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer;
ETFs that hold Repligen Corp
Repligen Corp is one of the ten largest holdings of one ETF that investors in Europe can buy:
| ETF | Weight | TER |
|---|---|---|
| First Trust NYSE Arca Biotechnology UCITS ETF Class A USD Accumulation | 4.06% | 0.60% |
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Repligen Corp's market cap?
Repligen Corp's market capitalization is USD 9.73B.
What is Repligen Corp's P/E ratio?
Repligen Corp's price-to-earnings (P/E) ratio is 235.1.
What does Repligen Corp do?
Repligen Corporation, a life sciences company, develops and commercializes bioprocessing technologies and systems in North America, Europe, the Asia Pacific, and internationally. The company's products include hollow fiber consumables, KRM chromatography system, resins for new modalities, PATsmart MAVERICK and PATsmart MAVEN for real-time monitoring and control of critical bioprocess parameters, PATsmart REBEL, an at-line cell culture media analyzer; and PATsmart ZipChip, a high-resolution sample separations device, PATsmart SoloVPE slope spectroscopy system, and SoloVPE PLUS System.